Q-omics provides the consensus-scored UBAC1 profile across patient tissues and cancer cell-line models. UBAC1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UBAC1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, UBAC1 RNA expression shows 19,083 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and THCA as cancer lineages where UBAC1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBAC1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBAC1 survival associations across molecular data types. UBAC1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBAC1 RNA expression–survival associations across cancer types. High UBAC1 expression shows unfavorable associations in ACC, LIHC, KIRC and COAD, but favorable associations in STAD and CESC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UBAC1 RNA expression.
This table summarizes UBAC1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for UBAC1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBAC1 shows lower tumor expression in THCA and higher tumor expression in LIHC, LUSC, CHOL, HNSC and ESCA. The THCA box plot shows higher UBAC1 RNA expression in normal versus tumor tissue (log2 FC = −0.199, t-test p < 0.001).
This table shows molecular features associated with UBAC1 in patient tissues and cancer cell lines. In patient samples, UBAC1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, UBAC1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
